Global Oncology Academy

ESR1 Mutations in Metastatic Breast Cancer: A Predictor of Poor Prognosis

ReachMD Healthcare Image
RestartResume

Here’s an in-depth review of key takeaways from a study focusing on ESR1 mutations in patients with metastatic breast cancer.

Take Post-Survey

If you’ve already completed the activity.

  • Overview

    Recent studies have examined the implications of ESR1 mutations in metastatic breast cancer and found that ESR1 mutations predict poor response to subsequent endocrine therapy. These acquired mutations also correlate with aggressive disease and, by extension, worse prognosis. Dive further into these findings from various studies and how they might impact the way we treat patients with metastatic breast cancer with Dr. Pavani Chalasani and Dr. Marcela Mazo Canola, Assistant Professor at UT Health San Antonio’s Mays Cancer Center.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free